Literature DB >> 21312273

Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease.

Bart Post1, Dino Muslimovic, Nan van Geloven, Johannes D Speelman, Ben Schmand, Rob J de Haan.   

Abstract

OBJECTIVE: To determine progression and prognostic factors of progression rate of motor impairment, disability, and quality of life (QoL) in patients with newly diagnosed Parkinson's disease.
METHODS: A group of 126 patients with newly diagnosed PD recruited from outpatient clinics participated in this 3-year prospective cohort study. Motor impairment was rated with the Unified Parkinson Disease Rating Scale Motor-Examination. Disability was rated using the Schwab and England Activities of Daily Living Scale, the AMC Linear Disability Score. QoL was assessed with the Parkinson's Disease Quality of Life questionnaire. Linear mixed model analyses were conducted to identify determinants of progression rate of motor impairment, disability, and poor QoL.
RESULTS: Motor impairment progressed with 3 points per year. There was a slight progression of disability and QoL during 3 years of follow-up. Female sex was a prognostic factor for slower progression of motor impairment and QoL. Older age at onset showed to prognosticate faster progression of disability and impaired QoL. Furthermore, independent of follow-up time, older age at onset was associated with worse motor impairment; nondopaminergic reactive symptoms (Axial impairment) were associated with more disability and poorer QoL; comorbidity showed relation with disability and QoL but to a lesser extent; self-reported mood symptoms were associated with poorer QoL; and disease duration correlated with motor impairment.
CONCLUSIONS: Motor impairment, disability, and QoL of newly diagnosed Parkinson patients show progression in the first 3 years. Older age at onset predicts worse progression rate of disability and impaired QoL over time. Female sex predicts slower progression of motor impairment and less decline of QoL.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21312273     DOI: 10.1002/mds.23467

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  24 in total

1.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

2.  Behavioral impairments and serotonin reductions in rats after chronic L-dopa.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

3.  The complexities of hormonal influences and risk of Parkinson's disease.

Authors:  Connie Marras; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2014-04-30       Impact factor: 10.338

Review 4.  Risk Factors for Malnutrition in Older Adults: A Systematic Review of the Literature Based on Longitudinal Data.

Authors:  Nádia Cristina Fávaro-Moreira; Stefanie Krausch-Hofmann; Christophe Matthys; Carine Vereecken; Erika Vanhauwaert; Anja Declercq; Geertruida Elsiena Bekkering; Joke Duyck
Journal:  Adv Nutr       Date:  2016-05-16       Impact factor: 8.701

5.  Heterogeneous pattern of autonomic dysfunction in Parkinson's disease.

Authors:  Laurène Leclair-Visonneau; Laurent Magy; Christelle Volteau; Thomas Clairembault; Séverine Le Dily; Cécile Préterre; Arnaud Peyre; Philippe Damier; Michel Neunlist; Yann Péréon; Pascal Derkinderen
Journal:  J Neurol       Date:  2018-02-20       Impact factor: 4.849

Review 6.  Spinal cord stimulation for Parkinson's disease: a systematic review.

Authors:  Emerson Magno de Andrade; Maria Gabriela Ghilardi; Rubens Gisbert Cury; Egberto Reis Barbosa; Romulo Fuentes; Manoel Jacobsen Teixeira; Erich Talamoni Fonoff
Journal:  Neurosurg Rev       Date:  2015-07-30       Impact factor: 3.042

7.  Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Roberto Erro; Gabriella Santangelo; Rosario Pivonello; Katia Longo; Claudia Pivonello; Carmine Vitale; Marianna Amboni; Marcello Moccia; Annamaria Colao; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

8.  A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study.

Authors:  Caroline M Tanner; Cheryl C Meng; Bernard Ravina; Anthony Lang; Roger Kurlan; Kenneth Marek; David Oakes; John Seibyl; Emily Flagg; Lisa Gauger; Dolores D Guest; Christopher G Goetz; Karl Kieburtz; Diane DiEuliis; Stanley Fahn; Robin A Elliott; Ira Shoulson
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

9.  Development and external validation of a prognostic model in newly diagnosed Parkinson disease.

Authors:  Daan C Velseboer; Rob M A de Bie; Luuk Wieske; Jonathan R Evans; Sarah L Mason; Thomas Foltynie; Ben Schmand; Rob J de Haan; Bart Post; Roger A Barker; Caroline H Williams-Gray
Journal:  Neurology       Date:  2016-02-17       Impact factor: 9.910

10.  The Key Determinants to Quality of Life in Parkinson's Disease Patients: Results from the Parkinson's Disease Biomarker Program (PDBP).

Authors:  Lu He; Eun-Young Lee; Nicholas W Sterling; Lan Kong; Mechelle M Lewis; Guangwei Du; Paul J Eslinger; Xuemei Huang
Journal:  J Parkinsons Dis       Date:  2016-05-31       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.